Form 8-K - Current report:
SEC Accession No. 0001104659-25-016725
Filing Date
2025-02-25
Accepted
2025-02-25 07:31:19
Documents
15
Period of Report
2025-02-21
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm257489d1_8k.htm   iXBRL 8-K 30239
2 EXHIBIT 99.1 tm257489d1_ex99-1.htm EX-99.1 83217
6 GRAPHIC tm257489d1_ex99-1img001.jpg GRAPHIC 19082
  Complete submission text file 0001104659-25-016725.txt   326584

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA knsa-20250221.xsd EX-101.SCH 3012
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE knsa-20250221_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE knsa-20250221_pre.xml EX-101.PRE 22357
17 EXTRACTED XBRL INSTANCE DOCUMENT tm257489d1_8k_htm.xml XML 3595
Mailing Address 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ
Business Address 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ 7814319100
Kiniksa Pharmaceuticals International, plc (Filer) CIK: 0001730430 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38492 | Film No.: 25659409
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)